Program

Preliminary

ISFA Vienna 2011
8th International Society for Apheresis Congress
3rd Wiener Aphereseseminar (Educational Program)

September 14th – 17th
University Hospital, Vienna - Austria

www.nephrologie.at

Congress Invitation – Letter from the President
To all people interested in apheresis
On behalf of the International Society for Apheresis (ISFA) it is my great pleasure to invite you to actively
participate in our upcoming congress to be held in Vienna, September 14th –17th, 2011.
We are grateful to Dr. Derfler and his colleagues for taking over the task to organize ISFA’s 8th international
congress. The congress will feature a great opportunity for you to update your knowledge base on apheresis
and to meet and interact with leading clinicians and researchers from around the world. For beginners and allied
health professionals there will be an Educational Program that will provide a comprehensive insight into theapheresis field. For the first time ISFA will honor best posters for specific topics immediately after the poster
sessions that will be guided by experienced apheresis experts.
September is the perfect time to visit Vienna. The capital of Austria is located in the heart of Europe and iseasily accessible by all kinds of transportation. It is a fascinating city that has preserved it’s rich history andculture you can sense around any corner. Together with the typical charm of the local people this characteristic
mixture makes Vienna so unique.
Mark the date in your calendar and plan to join us in Vienna next year. It is my personal belief that our next
congress will provide an exciting and productive atmosphere for all attendees allowing everyone to take home
new insights and unforgettable memories.
Wolfgang Ramlow, M.D.
President ISFA 2009–2011

Premium Sponsors

ISFA Vienna 2011www.nephrologie.at

WELCOME MESSAGE ISFA 2011

ISFA 2011 – Local Organizing Committee

Dear Colleagues, dear Friends!
On behalf of the local organizing team of the ISFA it is our pleasure and privilege to invite you to participate at
the 8th ISFA Congress to be performed in Vienna from September 14th to September 17th, 2011.
Vienna with its great scientific and cultural heritage and a centuries old tradition of hosting people of various
cultures certainly is predestined for organizing the ISFA Congress 2011. Located in the heart of Europe Vienna
also provides unique possibilities to explore Austria and other eastern as well as western countries of Europe.
The ISFA congress will be organized together with several other societies dedicated to extracorporeal treatment
modalities. This cooperation of various scientific communities will promote an interdisciplinary exchange of ideas
and experience, an integration of basic research and clinical medicine. Furthermore, a special educational program(including the 3rd “Wiener Aphereseseminar”) will be offered both for clinical scientist and for nurses in particular.
The congress will be located at the hospital of the Medical University of Vienna, which is easily accessible fromall parts of the city by underground.
Present day Vienna is a cosmopolitan, dynamic city with a booming cultural and economic life. With its richarchitecture, its famous opera house, numerous museums, the “Heurigen” wine taverns, an acclaimed Central
European “fusion cuisine”, Vienna can offer all participant of the ISFA Congress not only a high class scientificand educational program but also an extraordinary ambiance where you can relax, meet old and make newfriends and exchange ideas.
We are cordially inviting all of you to the 8th ISFA Congress in Vienna, Austria in 2011.
Prof. Kurt Derfler – President of the ISFA 2011 Congress
Prof. Wilfred Druml – Vice-President of the ISFA 2011 Congress
Prof. Sabine Schmaldienst – Vice-President of the ISFA 2011 Congress
Prof. Alice Schmidt – Congress Secretary

ISFA Vienna 2011www.nephrologie.at

Special Joint Organizing Committee
Derfler Kurt (Austria)
Congress President
Druml Wilfred (Austria)
Vice-President of the ISFA congress
Schmaldienst Sabine (Austria)
Vice-President of the ISFA congress
Schmidt Alice (Austria)
Congress Secretary
Ramlow Wolfgang (Germany)
Klinkmann Horst (Germany)
Nosé Yukihiko (USA)President ISFA 2009 –2011
Honorary Congress President
Honorary Congress President

ISFA Officers, the ISFA Board of Trustees and Members of the
Scientific Programme Committee ISFA Congress 14th –17th September 2011
Ramlow Wolfgang (Germany)
Tani Tohru (Japan)
Siami Ghodrat A. (USA)Figueroa Mario (Argentina)
Tsuda Hiroshi (Japan)
Derfler Kurt (Austria)
Endo Yoshihiro (Japan)
Akizawa Tadao (Japan)
Klinkmann Jens (Germany)
Kong Deling (PRC)
Lin Kuo-Juei (ROC)
Yonekawa Motoki (Japan)

President ISFA 2009 –2011
President electImmediate Past-President
Vice President
Vice President
Vice President
Secretary Treasurer
Editor in Chief: Ther Apheresis and Dialysis
Regional Officer Europe
Regional Officer Pan PacificRegional Officer Pan PacificRegional Officer Pan Pacific

America
Ash S.R. (USA)
Kaplan A. (USA)Malchesky P.S. (USA)Rock G. (Canada)

Hadsell A.T. (USA)
Khatri B.O. (USA)Moriarty P. (USA)Siami F.S. (USA)

Ivanovich P. (USA)Koo A. (USA)
Reddy R.L. (USA)
Torloni A.S. (USA)Pan-Pacific, Middle East and Asia
Al-Humaidan Hind A. (Saudi Arabia)
Han K.S. (Korea)
Lumlertgul D. (Thailand)
Nampoory N. (Kuwait)
Shoji H. (Japan)
Yamamoto T. (Japan)

Chiu H.C. (ROC)
Koga N. (Japan)
Matsumoto T. (Japan)
Sawada K. (Japan)
Suzuki Y. (Japan)
Yonekawa M. (Japan)

Fukunaga K. (Japan)
Kostner K. (Australia)
Mineshima M. (Japan)
Shibuya N. (Japan)
Xue J. (ROC)

EuropeAringer M. (Germany)
Böhmig G. (Austria)
Höcker P. (Austria)
Klinkmann J. (Germany)
Mansouri B. (Switzerland)
Ponikvar R. (Slovenia)
Schuff-Werner P. (Germany)
Stefanutti C. (Italy)
Szpirt W. (Denmark)Witt A. (Austria)

Baurmeister U. (Germany)
Emmerich J. (Germany)
Julius U. (Germany)
Knobler R. (Austria)
Moog R. (Germany)
Ramunni A. (Italy)
Sikole A. (Macedonia)
Stegmayr B. (Swweden)
Valenta R. (Austria)
Worel N. (Austria)

Biesenbach P. (Austria)
Falkenhagen D. (Austria)
Klingel R. (Germany)
Leitner G. (Austria)
Pokrovsky S.N. (Russia)
Rech J. (Germany)
Staudt A. (Germany)
Stummvoll G. (Austria)
Vogt A. (Germany)
Zillikens D. (Germany)

ISFA Vienna 2011www.nephrologie.at

PRELIMINARY MAIN TOPICS of ISFA 2011
Lipoprotein (LDL/Lp(a)) Apheresis
Different devices (Adsorption, Precipitation, Double Filtration; Single use versus reusable systems?)
Long term outcome of LDL-apheresis in homozygous and heterozygous familial hypercholesterolaemia
LDL-apheresis in children!
LDL-apheresis and additional medical treatment in children with homozygous familial hypercholesterolaemia (FH)
Additional medical treatment in adult patients with FH on LDL-apheresis
Hemorheological investigations in LDL-apheresis and related treatment options
Lp(a) and atherosclerotic vascular disease: Which patients are candidates for lipoprotein apheresis?
Results on Lp(a) removal by different treatment modalities?
Concomitant medical treatment for secondary prevention of cardiovascular disease in patients suffering fromelevated Lp(a)Strategies to identify high-risk atherosclerotic patients as candidates for lipoprotein apheresis therapy
Apheresis Therapy in Rheumatic disease
Plenary lecture: Autoantibodies in systemic rheumatic disease.
Immunoadsorption (IAS) in Lupus nephritis (including the long-term follow up of these patients)
IAS in anti-phospholipid – antibody syndrome
IAS in dermatomyositis and polymyositis (a prospective, multicenter study protocol will be presented at the stock
exchange at the congress)
IAS and plasma exchange in systemic vasculitis?
Additional immunosuppressive treatment in patients with rheumatic diseases on IAS
IAS in the Goodpasture Syndrome; Wegener’s disease?
Plasma exchange in ANCA associated vasculitis
The Status of Apheresis Therapy in Neurological Disease
Multiple Sclerosis
Neuromyelitis optica
Myasthenia gravis
CIDP
Cytapheresis
State of the art lecture: Cytapheresis in ulcerative colitis
Long-term cytapheresis therapy in refractory ulcerative colitis with acute flare
Efficacy and safety of cytapheresis treatment in patients with ulcerative colitis: the post marketing surveillanceof more than 600 patients in Japan
Laboratory test: predictive markers of response for cytapheresis treatment in active ulcerative colitis
Cytapheresis in Crohn’s disease
Cytapheresis in rheumatic diseases
Cytapheresis in skin diseases
Platelets – a new target for cytapheresis?
Photopheresis
Plenary lecture: Over two decades of extracorporeal photopheresis – state of the art lecture
Extracorporeal photopheresis: mechanism of action
Photopheresis in graft versus host disease
The role of photophersis in lung transplantation
Experience of photopheresis in cutaneous T-cell lymphoma
Extracorporeal Photopheresis in cutaneous T-cell lymphoma: the British experience
Apheresis Treatment in Dermatological Indications
Plenary lecture: Targeting IgE antibodies: A universal therapy for allergy?
IgE-apheresis for treatment of patients with hypersensitivity?
Immunoadsorption and Omalizumab in serious atopic dermatitis and allergic asthma bronchialis
Immunoadsorption in autoimmune bullous diseases

ISFA Vienna 2011www.nephrologie.at

PRELIMINARY MAIN TOPICS of ISFA 2011
ABO incompatible kidney transplantation
ABO-incompatible kidney transplantation – the Japanese experience
ABO-incompatible kidney transplantation – the Stockholm experience
ABO-incompatible kidney transplantation – the German experience
ABO-incompatible kidney transplantation – the Austrian experience
Immunoadsorption in solid organ transplantation / Apheresis in HLA-incompatible transplantation
Plenary session: Antibody-mediated transplant rejection
Treatment options for antibody-mediated rejection
Positive cross-match living donor kidney transplantation
Positive cross-match deceased donor kidney transplantation
Apheresis in thoracic organ transplantation
Therapeutic Apheresis in TTP (Thrombotic thrombocytopenic purpura): Any new options for TTP and
HUS (Hemolytic Uremic Syndrome)
Plasma Exchange, Immunoadsorption, Rituximab and New Drugs?
Clinical Trials in TTP / HUS: New Guidelines available?
New options for drug treatment in TTP?
Rituximab in TTP – The STAR-Trial – terminated due to serious side effects?
Concomitant Drug Treatment in Apheresis / Plasma Exchange Therapy
Immunoglobulins (IvIg)
Cytotoxic drug treatment / Cyclophosphamide, Cyclosporine A, Everolimus, Sirolimus, Mycophenolate Mofetil,
Azathioprine
Rituximab / Abatacept and New Drugs? Benefit and serious side effects?
Extracorporeal Treatment Modalities Mixed Session
Immunoadsorption in Pulmonary Arterial Hypertension (PAH)
Immunoadsorption in Thrombangitis Obliterans / auto-AB and results of a pilot study
Immunoadsorption in hemophiliacs with coagulation factor inhibitors
Double filtration plasmapheresis in chronic hepatitis C patients
Extracorporeal Treatment Options in Sepsis
Apheresis therapy in septic patients – The Japanese experience
Bioreactor therapy – a new approach to treat septic patients
Nanoparticles in sepsis therapy
Extracorporeal Liver Replacement Therapy
The MARS versus the PROMETHEUS System
Detailed analysis of the HELIOS Trial
Detailed presentation of the HRS-Study
Extracorporeal liver replacement therapy for treatment of severe pruritus due to advanced liver disease(A preliminary study protocol will be presented at the ISFA-congress stock exchange)
Approval and Reimbursement
National particularities vs. international harmonization
Apheresis Registries
Do apheresis registries really help treating our patients better?
The importance of prospective data collection for approval and reimbursement?
Clinical Trials Section
Current major trials – designs and expectations
Patient selection
Recent trials – outcome and lessons to be learned
Mode of Action of Immune Apheresis
Immunomodulation vs. Immunodepletion
The role of immunocompetent cells
Modification of immunocompetent cells
The role of AAB in certain diseases

ISFA Vienna 2011www.nephrologie.at
Printed in Austria by: ROBIDRUCK, 1200 Vienna – www.robidruck.co.at

General Information
REGISTRATION (online: www.nephrologie.at)
There are significant savings for early conference registration. For those registered by June 17th 2011, there will
be a reduced fee. For combined company registration a reduced conference fee is provided. ISFA members
receive a € 100 discount. The registration fee includes the costs of the congress, welcome reception, coffee
breaks, luncheons and the social evening event at the famous Rathaus of the city of Vienna. Furthermore a
supplement of Therapeutic Apheresis and Dialysis with all the abstracts will be provided. Fees may be paid bycredit card or cash.
ISFA congress and Educational Session (3rd Wiener Aphereseseminar)
Members
Non Members
For the complete congress (Early registration)
€ 300
€ 400
For the complete congress (Late registration)
€ 400
€ 500
One-day ticket
€ 150
€ 175
Nurses€ 150€ 175
Students€ 50€ 50
Company registration (N ≥ 10)€ 250/person€ 350/person
Company registration (N ≥ 15)€ 225/person€ 325/person
Educational Session (3rd Wiener Aphereseseminar)
Members
Total educational session€ 150
Nurses€ 100
Students€ 30
Company registration (N ≥ 10)€ 125
Company registration (N ≥ 15)€ 100

Non Members
€ 175
€ 125
€ 30
€ 150
€ 12S

A certificate of attendance will be provided at the registration counter, both for the ISFA congress and theeducational session (3rd Wiener Aphereseseminar).
Discount opportunities for CORPORATE MEMBERS of ISFA
Rental fee for industrial space 20% (regular € 400/m2).
Full registration fee waived for two company representatives.
Scientific Secretariat ISFA Vienna 2011
Prof. Sabine Schmaldienst, Prof. Alice Schmidt, Prof. Kurt Derfler
Medical University of Vienna
Dept. of Medicine III, Div. of Nephrology and Dialysis
Währinger Gürtel 18-20, A-1090 Vienna, Austria
Phone: +43 1 40400 4400
E-Mail: apheresewien@meduniwien.ac.at
Organizing Secretariat
Kuoni Destination Management Austria
Lerchenfelder Gürtel 43, A-1160 Vienna, Austria
Phone: +43 1 319 76 90-57, Fax: +43 1 319 11 80
E-Mail: ISFA2011@at.kuoni.com
Exhibition & Sponsoring
MAW – Medizinische Ausstellungs- und Werbegesellschaft
Freyung 6/3, A-1010 Vienna, Austria
Phone: +43 1 536 63-35, Fax: +43 1 535 60 16
E-Mail: maw@media.co.at
Location
The conference will be held at the General Hospital / AKH
Währinger Gürtel 18-20, 1090 Vienna, Austria
Hotel Accomodation and Social Program
For Details regarding hotel accommodation please visit our congress webpage.

ISFA Vienna 2011www.nephrologie.at

SPONSORS(as per printing date, August 15, 2010)

ISFA Vienna 2011www.nephrologie.at